Vertex Pharmaceuticals announced promising results from its stem cell-derived therapy for type 1 diabetes, with 10 of 12 patients able to discontinue insulin injections a year post-infusion. The therapy, zimislecel (formerly VX-880), involves delivering lab-grown insulin-producing islet cells to restore patients' endogenous insulin production. Presented at the American Diabetes Association meeting and published in the New England Journal of Medicine, these findings confirm durable efficacy and safety. This off-the-shelf cellular therapy represents a transformative approach to achieving glycemic control in type 1 diabetes.